HRA Raising Game To Promote UK OTC Daily Contraceptive, Hopes US Switch Will Follow
HBW Insight speaks to HRA Pharma CEO David Wright about the company's recent UK Rx-to-OTC contraceptive pill switch, it's signifcance for the global women's health category and the implications for a similar switch the company is pursuing in the US.
You may also be interested in...
The US Supreme Court’s overturning of Roe v. Wade, which enshrined the right to an abortion in the Constitution for almost 50 years, could have consequences that extend beyond access to termination of pregnancy.
“The only thing that keeps me up at night right now is labor shortages,” says CEO Murray Kessler. He also notes growing trend of consumers responding to inflation by moving from national brands to lower-priced private label/store brand OTC drugs.
Perrigo's HRA Pharma submits to FDA on 11 July an NDA by for OTC 0.075-mg norgestrel, branded Opill, The same formulation previously was available Rx 30 years.